Abstract
ObjectiveThe study aimed to evaluate the clinical outcomes of laparoscopic nerve-sparing radical hysterectomy (LNRH) for bulky-stage cervical cancer (lesion ≥ 6 cm) after neoadjuvant chemotherapy (NAC). MethodsThis study prospective recruited patients with pathology-confirmed cervical cancer presenting as a bulky mass (lesion ≥ 6 cm). Subjects included patients who underwent laparoscopic radical surgery. They were assigned to one of two groups by surgical method: patients who underwent LNRH after NAC and patients who underwent classical laparoscopic radical hysterectomy (LRH) after NAC. We compared the patients' general clinical characteristics, surgical profiles, pathological findings and adjuvant therapies between the two groups. Recovery of bladder and intestinal function was evaluated by questionnaire. Patients were followed for up to 1 year to determine the maintenance of effect. ResultsCompared with patients treated with LRH, patients who underwent LNRH presented no significant differences in age, surgery characteristics, pathological findings, adjuvant therapies or main adverse effects. The mean duration of residual urine <50 mL in the LNRH group was 11 days, much shorter than that in the LRH group (18 days; P < 0.001). The period of passage of gas by anus was shorter (38.9 ± 4.1 h) in LNRH patients than that in LRH patients (56.5 ± 4.0 h; P < 0.001). The urinary and intestinal symptoms were evaluated 1 year after surgery. The recovery of urinary and intestinal function of patients was better in the LNRH group than in the LRH group. ConclusionLNRH is a safe and feasible surgical management for bulky-stage cervical cancer patients (lesion ≥ 6 cm), and after NAC, the urinary and intestinal function of patients in LNRH group showed better recovery compared with functions in the LRH group. The technique is relatively new, and its oncologic efficiency has not yet been fully established. Prospective randomised controlled studies with an increased number of patients and long-term postoperative follow-up should be carried out to investigate the effect of this therapeutic strategy for bulky-stage cervical cancer.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
